Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 2 Study to Evaluate Three Treatment Regimens of SHAPE, a Histone Deacetylase Inhibitor, in Patients With Stage IA, IB or IIA Cutaneous T-Cell Lymphoma

NCT02213861 is registered in ClinicalTrials.gov with TetraLogic Pharmaceuticals as lead sponsor.

NCT NCT02213861
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02213861 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 2 Study to Evaluate Three Treatment Regimens of SHAPE, a Histone Deacetylase Inhibitor, in Patients With Stage IA, IB or IIA Cutaneous T-Cell Lymphoma
Lead sponsor
TetraLogic Pharmaceuticals
Phase
Phase 2
Overall status
Unknown status
Start date
November 30, 2014
Completion date
October 31, 2016
Enrollment
60 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous t-cell lymphoma (ctcl)